The differences in response to rapamycin between normal MECs and breast cancer cell lines could be due to differences in insulin-like growth factor receptors (IGFRs), which are expressed at higher levels in cancer cells and mediate feedback to Akt upon mTOR inhibition (Reviewed in [37–39]). This evidence concerns the gene MTOR and breast carcinoma.